Abstract:Human Immunodeficiency Virus (HIV) is the causative agent of Acquired Immunodeficiency Syndrome (AIDS) with high morbidity and mortality rates. Treatment of AIDS/HIV is being complicated by increasing resistance to currently used antiretroviral (ARV) drugs, mainly in low- and middle-income countries (LMICs) due to drug misuse, poor drug supply and poor treatment monitoring. However, progress has been made in the development of new ARV drugs, targeting different HIV components (Fig. 1). This review aims at presenting and discussing the progress made towards the discovery of new ARVs that are at different stages of clinical trials as of July 2024. For each compound, the mechanism of action, target biomolecule, genes associated with resistance, efficacy and safety, class, and phase of clinical trial are discussed. These compounds include analogues of nucleoside reverse transcriptase inhibitors (NRTIs) - islatravir and censavudine; non-nucleoside reverse transcriptase inhibitors (NNRTIs) - Rilpivirine, elsulfavirine and doravirine; integrase inhibitors namely cabotegravir and dolutegravir and chemokine coreceptors 5 and 2 (CC5/CCR2) antagonists for example cenicriviroc. Also, fostemsavir is being developed as an attachment inhibitor while lenacapavir, VH4004280 and VH4011499 are capsid inhibitors. Others are maturation inhibitors such as GSK-254, GSK3532795, GSK3739937, GSK2838232, and other compounds labelled as miscellaneous (do not belong to the classical groups of anti-HIV drugs or to the newer classes) such as obefazimod and BIT225. There is a considerable progress in the development of new anti-HIV drugs and the effort will continue since HIV infections has no cure or vaccine till now. Efforts are needed to reduce the toxicity of available drugs or discover new drugs with new classes which can delay the development of resistance.

Novel Drug Targets for Anti-Hiv-1 Therapy

Development of Anti-HIV Therapeutics: From Conventional Drug Discovery to Cutting-Edge Technology

The Research of Anti-HIV Drugs Small Molecular CCR5 Antagonist

Synthetic approaches and application of clinically approved small-molecule Anti-HIV drugs: An update

Recent Advances in Computer-aided Antiviral Drug Design Targeting HIV-1 Integrase and Reverse Transcriptase Associated Ribonuclease H

Current state-of-the-art in preclinical and clinical development of novel non-nucleoside HIV-1 reverse transcriptase inhibitors

The successes and failures of HIV drug discovery

Recent advances in natural anti‐HIV triterpenoids and analogs

Development Of Protein- And Peptide-Based Hiv Entry Inhibitors Targeting Gp120 Or Gp41

Opportunities and challenges in new HIV therapeutic discovery: what is the next step?

Current status of the small molecule anti-HIV drugs in the pipeline or recently approved

Recent advances on dual inhibitors targeting HIV reverse transcriptase associated polymerase and ribonuclease H

Recent Progress in HIV-1 Inhibitors Targeting the Entrance Channel of HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitor Binding Pocket

Pyridin-2(1H)-ones as HIV-1 NNRTIs: a combinatorial optimization strategy

HIV Biotherapy and Natural Chemotherapeutic Agents

Small-molecule HIV-1 Entry Inhibitors Targeting the Epitopes of Broadly Neutralizing Antibodies

Cellular proteins as potential targets for antiretroviral therapy

Deciphering the enigmas of non‐nucleoside reverse transcriptase inhibitors (NNRTIs): A medicinal chemistry expedition towards combating HIV drug resistance

Pharmacological advances in anti‐retroviral therapy for human immunodeficiency virus‐1 infection: A comprehensive review

Advanced Therapies for Human Immunodeficiency Virus

Recent advances in the development of small-molecule CCR5 inhibitors for HIV.